Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s Disease
Recordati Rare Diseases today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. Data from the LINC-4 study demonstrate that a significantly higher proportion of patients receiving Isturisa® achieve normal mUFC, the primary treatment goal for Cushing’s disease, after 12 weeks of treatment versus placebo (77% vs 8%; P <0.0001). 36 improvements in mufc levels are sustained over weeks of treatment (81% patients). isturisa® is well tolerated and has a manageable safety profile, with the most common adverse events linc-4 being arthralgia, decreased appetite, fatigue, nausea. findings from linc-4, first phase iii study medical therapy cushing’s disease to contain an upfront placebo-controlled phase, builds upon existing clinical evidence affirms effectiveness this hard-to-treat patient>1-3 0.0001).>
“Cushing’s disease is a chronic and debilitating condition that can be extremely challenging to manage and, if left inadequately treated, can have a significant impact on patients’ quality of life and increase the risk of mortality”, said Richard Feelders, MD, Professor of Endocrinology at the Erasmus University Medical Centre, Rotterdam. “Data from this important Phase III study show that Isturisa® (osilodrostat) is an effective and well-tolerated therapy for Cushing’s disease, which significantly reduces and normalizes mUFC levels in most patients. These data are encouraging given the high unmet medical need for patients with this rare disorder”.
“The compelling topline LINC-4 data confirm the effectiveness of Isturisa® for the treatment of this rare, potentially life-threatening disease”, stated Andrea Recordati, CEO. “We are deeply grateful to the patients, investigators, clinicians and study staff whose ongoing participation in the clinical development of Isturisa® has helped bring this therapy to patients in need.”
Data from the LINC 4 study reinforce the clinical benefits of Isturisa® as an effective and generally well‑tolerated oral treatment option for patients with Cushing’s disease.
About Cushing’s syndrome
Cushing’s syndrome is caused by an inappropriate and chronic exposure to excessive levels of cortisol. The source of this excess of cortisol can be endogenous or exogenous (ie medication). When the excess cortisol production is triggered by a pituitary adenoma (ie a tumor of the pituitary gland located in the brain) secreting excess adrenocorticotropic hormone (ACTH), the condition of the patient is defined as Cushing’s disease and comprises about 70% of Cushing’s syndrome cases.4 It is a rare, serious and difficult-to-treat disease that affects approximately one to two patients per million per year.5 Prolonged exposure to elevated cortisol levels is associated with considerable morbidity, mortality and impaired quality of life as a result of complications and comorbidities.6 Normalization of cortisol levels is therefore a primary objective in the treatment of Cushing’s syndrome.7
LINC-4 is a large randomized, double-blinded, multicentre, 48-week trial with an initial 12-week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease. The primary endpoint in the LINC-4 trial is the proportion of patients randomized to Isturisa® and placebo, separately, with a mUFC ≤ULN at the end of the 12-week placebo-controlled period. The key secondary endpoint is the proportion of patients in both arms combined with a mUFC ≤ULN after 36 weeks. LINC-4 involved 73 patients with persistent or recurrent Cushing’s disease or those with de novo disease who were not candidates for surgery.
Isturisa® is a potent oral inhibitor of 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal gland. Isturisa® will be available as 1-mg, 5-mg and 10-mg film-coated tablets. Isturisa®, indicated for the treatment of adult patients with endogenous Cushing’s syndrome (CS), is now available in France as the first EU country to launch. Isturisa® was granted marketing authorization by the European Commission (EC) on 9 January 2020. Please see prescribing information for detailed recommendations for the use of this product.8
- Bertagna X et al. J Clin Endocrinol Metab 2014;99:1375–83
- Fleseriu M et al. Pituitary 2016;19:138–48
- Biller BMK et al. Abstract OR16-2. Oral presentation at the Endocrine Society Annual Congress 2019
- Nieman LK et al. Am J Med 2005;118:1340
- Signifor® and Signifor® LAR Summary of Product Characteristics, June 2018
- Pivonello R et al. Lancet Diabetes Endocrinol 2016;4:611–29
- Nieman LK et al. J Clin Endocrinol Metab 2015;100:2807–31
- Isturisa® Summary of Product Characteristics, May 2020
About Recordati Rare Diseases
The company’s EMEA headquarters is located in Puteaux, France, with global headquarter offices located in Milan, Italy.
For a full list of products, please click here: www.recordatirarediseases.com/products .
About the Recordati group
Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SHIN-ETSU-CHEMICAL28.9.2020 08:02:09 CEST | Press release
Shin-Etsu Chemical Has Developed an Epoch-making Type of Molding Silicone Rubber That Does Not Require Post Cure
NTT-COMMUNICATIONS28.9.2020 08:02:09 CEST | Press release
NTT Com Demonstration Test to Link GAIA-X Platform’s “IDS Connector” Technology and SDPF Based on Data Trust®
CA-VERIMATRIX28.9.2020 07:17:26 CEST | Press release
US-Cable Operator Armstrong Turns To Verimatrix To Streamline & Secure VOD Launch
WIPRO-LIMITED27.9.2020 08:54:11 CEST | Press release
Spirit of Wipro Run Brings Together Thousands of Participants Globally
TENCENT-MARKETING25.9.2020 12:23:16 CEST | Press release
BCG Collaborates with Tencent Marketing Insight to Release 2020 BCG x Tencent Digital Luxury Report
NY-PHILIP-MORRIS-INTL25.9.2020 12:17:14 CEST | Press release
U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom